The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia–Related Bleeding

James R. Gossage

doi:10.1016/j.mayocp.2017.12.019

The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia–Related Bleeding

James R. Gossage

Pulmonary

Research output: Contribution to journal › Editorial › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	130-132
Number of pages	3
Journal	Mayo Clinic Proceedings
Volume	93
Issue number	2
DOIs	https://doi.org/10.1016/j.mayocp.2017.12.019
State	Published - Feb 2018

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.mayocp.2017.12.019

Cite this

@article{715891bad8564ca88b20d3e16916089e,

title = "The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia–Related Bleeding",

author = "Gossage, {James R.}",

year = "2018",

month = feb,

doi = "10.1016/j.mayocp.2017.12.019",

language = "English (US)",

volume = "93",

pages = "130--132",

journal = "Mayo Clinic Proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "2",

}

TY - JOUR

T1 - The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia–Related Bleeding

AU - Gossage, James R.

PY - 2018/2

Y1 - 2018/2

UR - http://www.scopus.com/inward/record.url?scp=85041105285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041105285&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2017.12.019

DO - 10.1016/j.mayocp.2017.12.019

M3 - Editorial

C2 - 29395348

AN - SCOPUS:85041105285

SN - 0025-6196

VL - 93

SP - 130

EP - 132

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

IS - 2

ER -

The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia–Related Bleeding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this